Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances
- PMID: 40307579
- DOI: 10.1038/s41417-025-00905-9
Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances
Abstract
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor in adults and has high mortality rates worldwide. GBM progression, treatment, and prognosis are influenced by the tumor microenvironment (TME), which includes immune, stromal, and tumor cells. Among them, glioblastoma-associated macrophages (GAMs) act as key regulators of GBM pathobiology. GAMs exhibit remarkable plasticity, as they can exhibit both protumor and antitumor effects. However, their function is determined by polarization and the TME. In this review, we provide a comprehensive overview of the current understanding of the biology of GAMs in GBM, including their origins, phenotypic diversity, and functional roles. We discuss the intricate crosstalk between GAMs and tumor cells, as well as other immune and stromal components, and highlight the mechanisms underlying GAM-mediated tumor progression, invasion, angiogenesis, and immune system evasion. Furthermore, we explore the therapeutic implications of targeting GAMs in GBM and discuss emerging strategies aimed at reprogramming GAMs toward an antitumorigenic phenotype or selectively depleting protumorigenic subsets. The final aim is to develop innovative therapeutic approaches that disrupt GBMs. By leveraging our increased understanding of GAM biology, we lay the foundation for transformative advances in GBM treatment to improve patient prognosis.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Consent for publication: All the authors have agreed on the contents of the manuscript.
Similar articles
-
Glioblastoma at the crossroads: current understanding and future therapeutic horizons.Signal Transduct Target Ther. 2025 Jul 9;10(1):213. doi: 10.1038/s41392-025-02299-4. Signal Transduct Target Ther. 2025. PMID: 40628732 Free PMC article. Review.
-
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages.Cancer Commun (Lond). 2025 Jun;45(6):677-701. doi: 10.1002/cac2.70016. Epub 2025 Mar 14. Cancer Commun (Lond). 2025. PMID: 40084746 Free PMC article.
-
Chemoradiation-Altered Micromilieu of Glioblastoma Cells Particularly Impacts M1-like Macrophage Activation.Int J Mol Sci. 2025 Jul 8;26(14):6574. doi: 10.3390/ijms26146574. Int J Mol Sci. 2025. PMID: 40724825 Free PMC article.
-
Rational therapeutic targeting of myeloid cells in glioblastoma: challenges and perspectives.Front Immunol. 2025 Jun 26;16:1472710. doi: 10.3389/fimmu.2025.1472710. eCollection 2025. Front Immunol. 2025. PMID: 40642066 Free PMC article. Review.
-
The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution.J Exp Clin Cancer Res. 2025 Jul 4;44(1):191. doi: 10.1186/s13046-025-03452-1. J Exp Clin Cancer Res. 2025. PMID: 40616096 Free PMC article.
Cited by
-
Therapeutic potential of targeting macrophages and microglia in glioblastoma.Trends Pharmacol Sci. 2025 Aug 9:S0165-6147(25)00149-X. doi: 10.1016/j.tips.2025.07.006. Online ahead of print. Trends Pharmacol Sci. 2025. PMID: 40784815 Review.
References
-
- Seyfrid M, Maich WT, Shaikh VM, Tatari N, Upreti D, Piyasena D et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. J Immunother Cancer 2022;10:e003289.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical